Keywords: ترماتینیب; Abdominal adhesions; Anti-fibrotic therapeutics; Trametinib; Mesothelial-mesenchymal transition; Fibronectin EDA isoform;
مقالات ISI ترماتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
Keywords: ترماتینیب; Low grade serous ovarian cancer; BRAF mutation; Dabrafenib; Trametinib;
MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model
Keywords: ترماتینیب; Pancreatic cancer; PDOX; Trametinib; Gemcitabine; Combination; Cancer resistance; Indvidualized therapy; Precision medicine;
UveÃtis y desprendimiento seroso de retina secundarios al tratamiento sistémico con dabrafenib y trametinib
Keywords: ترماتینیب; Dabrafenib; Trametinib; PanuveÃtis; Desprendimiento seroso de retina; Melanoma; Inhibidores MAPK; Dabrafenib; Trametinib; Panuveitis; Serous retinal detachment; Melanoma; MAPK inhibitors;
Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells
Keywords: ترماتینیب; KRAS-mutant lung adenocarcinoma; Survivin; p21; RB1; Trametinib;
How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma
Keywords: ترماتینیب; AZD6244; Binimetinib; MEK162; MEK inhibitor; Ocular melanoma; Selumetinib; Sotrastaurin; Trametinib; Uveal melanoma; Uveal neoplasms;
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity
Keywords: ترماتینیب; Dasatinib; Trametinib; KRAS; TAZ;
Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
Keywords: ترماتینیب; Melanoma; Chemotherapy; Vemurafenib; Dabrafenib; Trametinib; Metastatic; Unresectable; BRAF inhibitor; MEK inhibitor; Progression free survival (PFS); Median progression free survival;
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Keywords: ترماتینیب; Non-small cell lung cancer (NSCLC); BRAF mutations; Mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway; Vemurafenib; Dabrafenib; Trametinib;
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Keywords: ترماتینیب; Binimetinib (PubMED CID: 10288191); Cobimetanib (PubMED CID: 16222096); Dabrafenib: (PubMED CID: 44462760); Encorafenib: (PubMED CID; 50922675); Lifirafenib: (PubMED CID:89670174); LY3009120 (PubMED CID: 71721540); PLX7904: (PubMED CID: 901169945); Sorafe
Les nouveaux médicaments en cancérologie
Keywords: ترماتینیب; cancérologie; ponatinib; tramétinib; oncology; ponatinib; trametinib;
Current PerspectiveThe 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients
Keywords: ترماتینیب; Melanoma; Adjuvant therapy; Randomised trials; Nivolumab; Ipilimumab; Dabrafenib; Trametinib;
BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome
Keywords: ترماتینیب; Dabrafenib; melanoma; trametinib; podocyte injury; glomerulopathy; nephrotic syndrome; BRAF inhibitor; MEK inhibitor; targeted cancer therapy; BRAF signaling pathway; proteinuria; PLCε1; renal biopsy; nephrotoxicity; case report;
Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma
Keywords: ترماتینیب; Trametinib; Tim-3; MAPK pathway; Targeted therapy; Cancer immunotherapy; MAPK; mitogen-activated protein kinase; MEK; mitogen-activated extracellular signal-regulated kinase; OS; overall survival; CTLA-4; cytotoxic T lymphocyte antigen-4; PD-1; programmed
Original ArticleBIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines
Keywords: ترماتینیب; Melanoma; Vemurafenib; Trametinib; BIK/NBK; Apoptosis;
(Neo)adjuvant systemic therapy for melanoma
Keywords: ترماتینیب; Cutaneous melanoma; High risk melanoma; Melanoma; Adjuvant; Neoadjuvant; Immunotherapy; Anti CTLA-4; Ipilimumab; BRAF inhibitor; Vemurafenib; Dabrafenib; MEK inhibitor; Trametinib; Cobimetinib; Anti PD1; T-VEC; Tamilogene Laherparepvec; Review;
Original ResearchThree-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Keywords: ترماتینیب; Dabrafenib; Trametinib; Vemurafenib; Melanoma; Multivariate analysis;
Original ArticleEverolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH
Keywords: ترماتینیب; Acidosis; Tumor microenvironment; BRAFV600E melanoma cells; Vemurafenib; Trametinib; Everolimus; MAPK; mitogen-activated protein kinase; RTK; receptor tyrosine kinases; ERK; extracellular signal-regulated kinases; PI3K; phosphatidylinositol 3-kinase; AKT;
Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma
Keywords: ترماتینیب; 4-Methylumbelliferone; CD44; ERK; Malignant pleural mesothelioma; Trametinib;
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer
Keywords: ترماتینیب; Trametinib; MEK inhibitor; NSCLC; KRAS mutations;
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)
Keywords: ترماتینیب; Acalabrutinib; Alectinib; Brigatinib; Ceritinib; Crizotinib; Dabrafenib; Dasatinib; Erlotinib; Gefitinib; Ibrutinib; Imatinib; Lorlatinib; Nilotinib; Osimertinib; Rociletinib; Trametinib; Vemurafenib;
PAPS PaperMEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy
Keywords: ترماتینیب; Neuroblastoma; RAS-ERK pathway; MEK inhibitor; RAF/MEK inhibitor; Trametinib; CH5126766;
Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic
Keywords: ترماتینیب; Drosophila; non-small-cell lung cancer; trametinib; fluvastatin; trachea
Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib to Allow Complete Surgical Resection in Patients With BRAF Mutated
Keywords: ترماتینیب; Dabrafenib; Locally advanced; Melanoma; Neo-adjuvant; Surgery; Trametinib;
Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry
Keywords: ترماتینیب; Dabrafenib; Trametinib; Therapeutic drug monitoring; Pharmacokinetics; HPLC-MS/MS;
Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-α production and endotoxin shock
Keywords: ترماتینیب; Lipopolysaccharide (LPS); Trametinib; Tumor necrosis factor (TNF)-α; MEK-ERK signaling and endotoxin shock;
PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel
Keywords: ترماتینیب; Melanoma; MEK; BRAF; Trametinib; Trial; Phase 1;
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
Keywords: ترماتینیب; Melanoma; Protein kinase inhibitors; Molecular targeted therapy; Proto-oncogene proteins B-raf; Dabrafenib; Trametinib;
BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer
Keywords: ترماتینیب; BRAF; V600E; MEK; Vemurafenib; Dabrafenib; Trametinib; Non-small-cell lung cancer;
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
Keywords: ترماتینیب; Melanoma; BRAF; MEK; Vemurafenib; Dabrafenib; Trametinib
Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence
Keywords: ترماتینیب; Trametinib; GSK 1120212; MEK inhibitor; Radiosensitization; Senescence;
MEK inhibition in non-small cell lung cancer
Keywords: ترماتینیب; KRAS mutation; Targeted therapy; MEK inhibition; Selumetinib; Trametinib; Clinical trials;
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Keywords: ترماتینیب; Gemcitabine; MEK inhibitor; Trametinib; Pancreas; Randomised
COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors
Keywords: ترماتینیب; Squamous cell carcinomas; COX-2; celecoxib; vemurafenib; trametinib;
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Keywords: ترماتینیب; Trametinib; MAP kinase; Gemcitabine; MEK inhibitor; GSK1120212;